NASDAQ:SGEN

Seagen - SGEN Stock Forecast, Price & News

$122.96

-0.48 (-0.39%)

(As of 11/28/2022 01:03 PM ET)

Add

Compare

Today's Range: $122.75
▼
$125.03
50-Day Range: $123.44
▼
$141.99
52-Week Range: $105.43
▼
$183.00

Volume: 8,693 shs
Average Volume: 1.14 million shs
Market Capitalization: $22.83 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $160.67

Seagen MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 29.7% Upside
$160.67 Price Target
Short Interest: Healthy
1.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.87
Upright™ Environmental Score
News Sentiment: 0.45
Based on 3 Articles This Week
Insider Trading: Selling Shares
$3.41 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.54) to ($2.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

91st out of 1,040 stocks

Biological Products, Except Diagnostic Industry

10th out of 175 stocks

4.4

Analyst's Opinion

Consensus Rating
Seagen has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $160.67, Seagen has a forecasted upside of 29.7% from its current price of $123.87.
Amount of Analyst Coverage
Seagen has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.34% of the outstanding shares of Seagen have been sold short.
Short Interest Ratio / Days to Cover
Seagen has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Seagen has recently increased by 6.90%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Seagen does not currently pay a dividend.
Dividend Growth
Seagen does not have a long track record of dividend growth.

3.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Seagen has received a 44.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Brentuximab vedotin", "Tucatinib", and "Enfortumab vedotin" products. See details.
Environmental Sustainability
The Environmental Impact score for Seagen is -1.87.

1.4

News and Social Media Coverage

News Sentiment
Seagen has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Seagen this week, compared to 7 articles on an average week.
Search Interest
Only 4 people have searched for SGEN on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Seagen to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Seagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,410,290.00 in company stock.
Percentage Held by Insiders
27.30% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.21% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Seagen are expected to grow in the coming year, from ($3.54) to ($2.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Seagen is -35.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Seagen is -35.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Seagen has a P/B Ratio of 7.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Seagen (NASDAQ:SGEN) Stock

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Stock News Headlines

November 25, 2022 | americanbankingnews.com

Seagen Inc. (NASDAQ:SGEN) Receives $160.67 Consensus Target Price from Analysts

November 17, 2022 | finance.yahoo.com

Institutional owners may consider drastic measures as Seagen Inc.'s (NASDAQ:SGEN) recent US$1.2b drop adds to long-term losses

November 10, 2022 | finance.yahoo.com

Seagen Names David R. Epstein as Chief Executive Officer and Director

November 10, 2022 | finance.yahoo.com

Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

November 10, 2022 | finance.yahoo.com

Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

November 10, 2022 | finance.yahoo.com

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

October 31, 2022 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Seagen (SGEN), Alnylam Pharma (ALNY) and BioMarin Pharmaceutical (BMRN)

October 27, 2022 | nasdaq.com

Seagen Inc Q3 Loss decreases, but misses estimates

October 27, 2022 | seekingalpha.com

Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript

October 27, 2022 | finance.yahoo.com

Seagen Reports Third Quarter 2022 Financial Results

October 25, 2022 | msn.com

A Bearish Sign Appears On Seagen's Chart

October 25, 2022 | msn.com

What 9 Analyst Ratings Have To Say About Seagen

October 19, 2022 | finance.yahoo.com

Investing in Seagen (NASDAQ:SGEN) five years ago would have delivered you a 116% gain

October 18, 2022 | seekingalpha.com

LAVA Therapeutics: Assessing A Promising Innovator (NASDAQ:LVTX) - Seeking Alpha

October 13, 2022 | benzinga.com

What 8 Analyst Ratings Have To Say About Seagen - Seagen (NASDAQ:SGEN) - Benzinga

October 13, 2022 | benzinga.com

Morgan Stanley Maintains Overweight Rating for Seagen: Here's What You Need To Know - Seagen (NASDAQ:SGEN - Benzinga

October 13, 2022 | finance.yahoo.com

New Veeva Link Applications Give Clinical Teams Real-Time Intelligence to Optimize Site Selection and Trial Design - Yahoo Finance

October 12, 2022 | fool.com

Is Seagen Stock a Buy Now? - The Motley Fool

October 12, 2022 | nasdaq.com

Is Seagen Stock a Buy Now? - Nasdaq

October 11, 2022 | benzinga.com

BMO Capital Upgrades Seagen: Here's What You Need To Know - Seagen (NASDAQ:SGEN) - Benzinga

October 7, 2022 | businesswire.com

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022 - Business Wire

October 7, 2022 | nasdaq.com

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

October 6, 2022 | benzinga.com

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October - Benzinga

October 6, 2022 | finance.yahoo.com

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022 - Yahoo Finance

October 6, 2022 | finance.yahoo.com

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Company Calendar

Last Earnings: 10/28/2021
Today: 11/28/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/08/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:SGEN
CUSIP: 81257810
CIK: 1060736
Web: www.seattlegenetics.com
Phone: (425) 527-4000
Fax: 425-527-4001
Employees: 2,675
Year Founded: 1998

Price Target and Rating

Average Stock Price Forecast: $160.67
High Stock Price Forecast: $188.00
Low Stock Price Forecast: $135.00
Forecasted Upside/Downside: +30.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.73
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-674,470,000.00
Net Margins: -34.16%
Pretax Margin: -34.09%
Return on Equity: -21.56%
Return on Assets: -17.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.80
Quick Ratio: 3.30

Sales & Book Value

Annual Sales: $1.57 billion
Price / Sales: 14.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.76 per share
Price / Book: 7.34

Miscellaneous

Outstanding Shares: 185,665,000
Free Float: 134,978,000
Market Cap: $22.83 billion
Optionable: Optionable
Beta: 0.60

Social Links

Key Executives

Dr. Roger D. Dansey M.D. (Age 66)
Chief Medical Officer & Interim CEO
Comp: $1.53M

Mr. Todd E. Simpson (Age 61)
Chief Financial Officer
Comp: $1.17M

Ms. Jean I. Liu J.D. (Age 54)
M.S., Chief Legal Officer
Comp: $1.11M

Mr. Charles R. Romp (Age 54)
Exec. VP of Commercial U.S.
Comp: $1.02M

Dr. Vaughn B. Himes Ph.D. (Age 61)
Chief Technical Officer

Peggy Pinkston
Sr. VP of Investor Relations

Mr. David Caouette
VP of Corp. Communications

Mr. Matt Skelton
VP of Marketing

Mr. Christopher P. Pawlowicz
Exec. VP of HR

Ms. Natasha A. Hernday (Age 50)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SGEN Stock - Frequently Asked Questions

Should I buy or sell Seagen stock right now?: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SGEN shares.
View SGEN analyst ratings or view top-rated stocks.
What is Seagen's stock price forecast for 2023?: 15 brokers have issued 12-month target prices for Seagen's stock. Their SGEN share price forecasts range from $135.00 to $188.00. On average, they predict the company's share price to reach $160.67 in the next year. This suggests a possible upside of 30.2% from the stock's current price.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.
How have SGEN shares performed in 2022?: Seagen's stock was trading at $154.60 on January 1st, 2022. Since then, SGEN stock has decreased by 20.2% and is now trading at $123.44.
View the best growth stocks for 2022 here.
When is Seagen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our SGEN earnings forecast.
How were Seagen's earnings last quarter?: Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Thursday, October, 28th. The biotechnology company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($0.56) by $1.05. The biotechnology company earned $424.60 million during the quarter, compared to analyst estimates of $384.83 million. Seagen had a negative net margin of 34.16% and a negative trailing twelve-month return on equity of 21.56%. The company's revenue was down 60.0% on a year-over-year basis. During the same period in the previous year, the company earned $3.50 earnings per share.
What guidance has Seagen issued on next quarter's earnings?: Seagen updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.82 billion-$1.86 billion, compared to the consensus revenue estimate of $1.84 billion.
What is Clay B. Siegall's approval rating as Seagen's CEO?: 107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).
What is Seagen's stock symbol?: Seagen trades on the NASDAQ under the ticker symbol "SGEN."
Who are Seagen's major shareholders?: Seagen's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.82%), BlackRock Inc. (6.37%), Primecap Management Co. CA (2.47%), State Street Corp (1.86%), Bank of New York Mellon Corp (0.54%) and Macquarie Group Ltd. (0.50%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends.
How do I buy shares of Seagen?: Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Seagen's stock price today?: One share of SGEN stock can currently be purchased for approximately $123.44.
How much money does Seagen make?: Seagen (NASDAQ:SGEN) has a market capitalization of $22.92 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674,470,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis.
How many employees does Seagen have?: The company employs 2,675 workers across the globe.
Does Seagen have any subsidiaries?: The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
How can I contact Seagen?: Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.

This page (NASDAQ:SGEN) was last updated on 11/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Seagen - SGEN Stock Forecast, Price & News

Seagen MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Seagen (NASDAQ:SGEN) Stock

SGEN Stock News Headlines

SGEN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

SGEN Stock - Frequently Asked Questions

Overall MarketRank^™